Literature DB >> 19018697

Cord blood stem cell therapy for acquired immune deficiency syndrome.

Gabriel Gonzalez1, Elizabeth J Shpall, Joseph C Gathe, Richard R Behringer.   

Abstract

Cord blood stem cell transplantation is routinely used to treat hematopoietic diseases. Individuals who are homozygous for the 32 polymorphism of the CCR5 locus, encoding a co-receptor for HIV-1, are normal and are resistant to HIV infection. Here we suggest that public cord blood repositories are likely to contain CCR5 homozygous units that could be used as a therapy for HIV-infected individuals.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19018697      PMCID： PMC3141738          DOI： 10.1089/scd.2008.0304

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN： 1547-3287            Impact factor:   3.272


  13 in total

1.  The coreceptor mutation CCR5Delta32 influences the dynamics of HIV epidemics and is selected for by HIV.

Authors:  A D Sullivan; J Wigginton; D Kirschner
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-21       Impact factor: 11.205

Review 2.  Targeting chemokine receptors in HIV: a status report.

Authors:  Shawn E Kuhmann; Oliver Hartley
Journal:  Annu Rev Pharmacol Toxicol       Date:  2008       Impact factor: 13.820

3.  Phenotypic expressions of CCR5-delta32/delta32 homozygosity.

Authors:  G T Nguyêñ; M Carrington; J A Beeler; M Dean; L M Aledort; P M Blatt; A R Cohen; D DiMichele; M E Eyster; C M Kessler; B Konkle; C Leissinger; N Luban; S J O'Brien; J J Goedert; T R O'Brien
Journal:  J Acquir Immune Defic Syndr       Date:  1999-09-01       Impact factor: 3.731

4.  Global distribution of the CCR5 gene 32-basepair deletion.

Authors:  J J Martinson; N H Chapman; D C Rees; Y T Liu; J B Clegg
Journal:  Nat Genet       Date:  1997-05       Impact factor: 38.330

Review 5.  Cord blood immunology and stem cell transplantation.

Authors:  M Brigid Bradley; Mitchell S Cairo
Journal:  Hum Immunol       Date:  2005-02-26       Impact factor: 2.850

6.  Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene.

Authors:  M Samson; F Libert; B J Doranz; J Rucker; C Liesnard; C M Farber; S Saragosti; C Lapoumeroulie; J Cognaux; C Forceille; G Muyldermans; C Verhofstede; G Burtonboy; M Georges; T Imai; S Rana; Y Yi; R J Smyth; R G Collman; R W Doms; G Vassart; M Parmentier
Journal:  Nature       Date:  1996-08-22       Impact factor: 49.962

Review 7.  HIV-1 infection in individuals with the CCR5-Delta32/Delta32 genotype: acquisition of syncytium-inducing virus at seroconversion.

Authors:  Haynes W Sheppard; Connie Celum; Nelson L Michael; Stephen O'Brien; Michael Dean; Mary Carrington; Dale Dondero; Susan P Buchbinder
Journal:  J Acquir Immune Defic Syndr       Date:  2002-03-01       Impact factor: 3.731

8.  Role for CCR5Delta32 protein in resistance to R5, R5X4, and X4 human immunodeficiency virus type 1 in primary CD4+ cells.

Authors:  Lokesh Agrawal; Xihua Lu; Jin Qingwen; Zainab VanHorn-Ali; Ioan Vlad Nicolescu; David H McDermott; Philip M Murphy; Ghalib Alkhatib
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

9.  Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study.

Authors:  M Dean; M Carrington; C Winkler; G A Huttley; M W Smith; R Allikmets; J J Goedert; S P Buchbinder; E Vittinghoff; E Gomperts; S Donfield; D Vlahov; R Kaslow; A Saah; C Rinaldo; R Detels; S J O'Brien
Journal:  Science       Date:  1996-09-27       Impact factor: 47.728

10.  New approaches in the treatment of HIV/AIDS - focus on maraviroc and other CCR5 antagonists.

Authors:  Hans P Schlecht; Sarah Schellhorn; Bruce J Dezube; Jeffrey M Jacobson
Journal:  Ther Clin Risk Manag       Date:  2008-04       Impact factor: 2.423
View more
  2 in total

1.  Identification and frequency of CCR5Δ32/Δ32 HIV-resistant cord blood units from Houston area hospitals.

Authors:  G Gonzalez; Ss Park; Dw Chen; S Armitage; Ej Shpall; Rr Behringer
Journal:  HIV Med       Date:  2011-03-06       Impact factor: 3.180

2.  Contamination of mesenchymal stem-cells with fibroblasts accelerates neurodegeneration in an experimental model of Parkinson's disease.

Authors:  Marcia C L Pereira; Mariane Secco; Daniela E Suzuki; Luciana Janjoppi; Carolina O Rodini; Layla B Torres; Bruno H S Araújo; Esper A Cavalheiro; Mayana Zatz; Oswaldo Keith Okamoto
Journal:  Stem Cell Rev Rep       Date:  2011-11       Impact factor: 5.739
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.